Aakash Desai: The ADC Bottleneck Is Shifting From Drug Availability to Patient Selection
Aakash Desai/LinkedIn

Aakash Desai: The ADC Bottleneck Is Shifting From Drug Availability to Patient Selection

Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on LinkedIn:

“87 antibody-drug targets, more than 32,000 specimens.

A new Cancer Discovery AACR Journals atlas argues the ADC bottleneck is shifting from drug availability to patient selection.

  • Solid-tumor antigens profiled for prevalence, heterogeneity, internalization and payload-sensitivity pathways
  • ReSort, a two-tiered score: virtual basket/umbrella trial matching, concordant with clinical assays, predicts response in patient-derived models
  • AI decision-support agent for antibody trial matching

When we mapped 47 active lung ADC/BsAb trials, the same few antigens kept showing up. A score like ReSort matters only if trials use it to pick patients prospectively; the matching here is still virtual.

What would it take to write a ReSort-style score into ADC trial eligibility?”

Title: Systematic Characterization of Clinically Actionable Antibody-Drug Targets Across Solid Tumors to Advance Precision Oncology

Authors: Zhongyi Hu, Yanrong Sun, Jiao Yuan, Tong Su, Yuxin Wang, Jie Huang, Eleanor Taranto, Junjie Jiang, Junjie Nie, Meixiao Long, Jennifer Q. Zhang, Janos L. Tanyi, Yi Fan, Ravi K. Amaravadi, Jeffrey Kaufman, Josh Sommer, Nicole Spardy. Burr, Daniel M. Freed, EnJun Yang, Christopher R. Cabanski, Hongzhe Li, Kathleen T. Montone, Sarah H. Kim, Angela DeMichele, Susan M. Domchek, Xiaowen Hu, Robert H. Vonderheide, Lin Zhang

Read the Full Article on Cancer Discovery 

Aakash Desai: The ADC Bottleneck Is Shifting From Drug Availability to Patient Selection

You can also read: Biomarker Landscape of ADCs and Bispecific Antibodies in Lung Cancer: The 2026 Clinical Trial Evidence and Future of Precision Treatment

Aakash Desai: The ADC Bottleneck Is Shifting From Drug Availability to Patient Selection